Phase
Condition
Urinary Incontinence
Bladder Disorders
Urinary Tract Infections
Treatment
N/AClinical Study ID
Ages 18-75 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Female outpatients aged 18-75 years
Diagnosis of acute lower uUTI occurring for the first time or acute relapse of chronicrecurrent uUTI
Typical symptoms of cystitis (pollakisuria, dysuria and urgency)
Bacterial count of 104 - 106 colony forming units (CFU)/mL in midstream urine
Presence of >20 leukocytes/µL of urine measured by dipstick test
No antibiotic treatment required according to the investigator
Women of childbearing potential were allowed to participate only if they used a highlyeffective method of contraception
Written informed consent
Exclusion
Exclusion Criteria:
Known hypersensitivity to any of the active substances or excipients of the studymedication
Antibiotic treatment during the past 8 days or indication for antibiotic treatment forthe current infection
Patients with trichomoniasis, chlamydiosis or gonorrhoea
Use of concomitant medication that may have an effect on the UTI, including otherphytotherapeutics with similar effects, saluretics (including those inantihypertensives) or other drugs with a similar mode of action, urinary acidifyingagents (e.g. Acimethin®), antibiotics, or phytotherapeutics with possible antibioticeffects
Patients with suspected ovarian inflammation (e.g. adnexitis)
Patients with suspected renal inflammation (e.g. pyelonephritis)
Patients with complicated UTI (e.g. obstruction, stones, reflux)
Patients with overactive bladder
Patients with vegetative urogenital syndrome
Patients who were currently participating or had participated in another clinicaltrial within 30 days before enrolment
Patients in poor general condition
Alcohol- or drug-addicted patients
Pregnant or nursing women or women not using highly effective methods of contraception
Patients with mental illness or no/limited legal capacity
Patients held in an institution by legal or official order
Patients who were not proficient in spoken or written German
Patients with a urine bacterial count >10*6 CFU/mL were to be excluded from furtherparticipation in the study unless they specifically wished to continue treatment withthe study medication.
No contraindications against the study medication were known at the time of studyprotocol preparation